Clinical Trial Update: Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy [NA]

View source ↗

Summary

A clinical trial update noting recruitment for a study evaluating telemonitoring to manage side effects in patients with melanoma, lung cancer, or renal cell ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Melanoma
• Renal Cell Carcinoma

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Melanoma, Lung Cancer | NA | Status: RECRUITING